ASP Isotopes Signs MOU with U.S. Energy Company
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 06 2026
0mins
Should l Buy ASPI?
ASP Isotopes announced that Quantum Leap Energy has entered into a non-binding Memorandum of Understanding, MOU, with a large publicly traded U.S. energy company that operates nuclear power stations. Under the terms of the MOU, the U.S. energy company will evaluate options to support QLE's plans to establish advanced nuclear fuel cycle facilities located in the United States. These facilities are planned to produce high assay low enriched uranium and low enriched uranium plus, as well as to provide uranium conversion and deconversion services. The MOU outlines potential terms for providing financial support pursuant to definitive agreements for the supply of enriched uranium.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASPI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASPI
Wall Street analysts forecast ASPI stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.280
Low
11.00
Averages
12.00
High
13.00
Current: 5.280
Low
11.00
Averages
12.00
High
13.00
About ASPI
ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. Its proprietary technologies, the Aerodynamic Separation Process and Quantum Enrichment technology, are designed to enable the production of isotopes used in several industries. Its initial focus is on the production and commercialization of enriched Carbon-14 (C-14), Silicon-28 (Si-28) and Ytterbium-176 (Yb-176). It is also a provider of liquid helium with operations at the Virginia Gas Project in South Africa. Its nuclear fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its specialist isotopes and related services segment is focused on research and development of technologies and methods used to separate isotopes for highly specialized target end markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The class action against ASP Isotopes (NASDAQ: ASPI) continues after the Southern District of New York partially denied the defendants' motion to dismiss, indicating potential legal liabilities for the company and its executives, which could undermine investor confidence.
- False Statement Allegations: The lawsuit alleges that the company made materially false and misleading statements regarding its uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which may have long-term implications for its financial health.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, highlighting the potential impact of legal actions on corporate governance structures.
- Market Reaction: As the lawsuit progresses, investor confidence in the company's future may wane, leading to stock price volatility, reflecting the market's heightened scrutiny of the company's transparency and compliance.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The class action against ASP Isotopes Inc. (NASDAQ: ASPI) survives a partial dismissal motion in the Southern District of New York, indicating that securities fraud allegations against the company and its executives remain valid, potentially exposing the company to significant legal liabilities.
- False Statement Allegations: The lawsuit alleges that the company made materially false and misleading statements regarding its uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which could lead to severe losses for investors.
- Shareholder Rights Protection: Shareholders holding ASP Isotopes stock can seek corporate reforms and fund recovery at no cost, providing a legal remedy for affected investors that may influence the company's future governance structure.
- Market Reaction Potential: As the lawsuit progresses, market confidence in ASP Isotopes may be affected, leading to stock price volatility, prompting investors to closely monitor developments to assess potential financial impacts and investment risks.
See More
Investigation into ASP Isotopes Shareholder Rights
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of ASP Isotopes Inc. breached their fiduciary duties to shareholders, potentially impacting corporate governance and shareholder rights.
- Legal Fee Arrangement: The firm commits to handling matters on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal fees, thereby reducing the financial burden of participation.
- Importance of Participation: Shareholder involvement can drive improvements in company policies and oversight mechanisms, enhancing transparency and accountability, which ultimately boosts shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors.
See More
ASP Isotopes Stock Rises on Nuclear Energy Agreement
- Stock Surge: ASP Isotopes Inc. (NASDAQ:ASPI) shares rose 6.65% to $5.45 today after announcing a non-binding memorandum of understanding with a large U.S. energy company, indicating strong market optimism regarding future collaborations.
- Annual Performance: The stock has increased by 37.19% over the past year, although it remains closer to its 52-week low than its high, suggesting that investor interest in the company's nuclear energy potential could drive future price recovery.
- Technical Indicator Analysis: Currently, ASPI is trading 2.8% above its 20-day simple moving average but 22.2% below its 100-day average, reflecting a short-term bounce while indicating that the long-term trend still requires improvement, prompting cautious investor sentiment.
- Future Earnings Outlook: The upcoming earnings report on March 30, 2026, is expected to show an EPS loss of 14 cents with revenue estimated at $2.03 million, up from $1.19 million year-over-year, suggesting that while profitability remains a challenge, market confidence in future growth may strengthen.
See More
Quantum Leap Energy Signs Agreement with Utility for Nuclear Fuel Production
- Nuclear Fuel Production Expansion: Quantum Leap Energy has signed a memorandum of understanding with an unnamed utility to develop advanced nuclear fuel cycle facilities in the U.S., focusing on producing high-assay low-enriched uranium (HALEU) and low-enriched uranium plus (LEU+), which are essential for next-generation reactors, thereby enhancing domestic nuclear fuel production capabilities.
- Supporting Future Reactor Designs: The agreement aims to support next-generation reactor technologies and is expected to supply LEU+ fuel to existing nuclear facilities currently using conventional low-enriched uranium, reflecting a commitment to strengthening domestic nuclear fuel production and reducing reliance on overseas suppliers.
- Rising Market Demand: As developers work on advanced reactors and small modular designs, the demand for enriched uranium is increasing, with industry participants and policymakers emphasizing the importance of bolstering domestic production to meet future energy needs.
- Positive Market Reaction: ASPI's stock rose 0.7% in Friday's premarket trading, and retail sentiment on Stocktwits shifted from 'bearish' to 'neutral', indicating growing market confidence in the company's future prospects.
See More
RedChip Show to Feature Interviews with TMC and ASPI
- TMC's Strategic Role: TMC CFO Craig Shesky emphasized the company's importance in addressing U.S. critical mineral dependence during the RedChip show, particularly through the development of polymetallic nodule resources in the Clarion Clipperton Zone, which could provide a long-term domestic supply of nickel, copper, cobalt, and manganese, thereby enhancing the U.S.'s strategic position amid geopolitical competition.
- Regulatory Framework Progress: Shesky noted TMC's advancements under the U.S. Deep Seabed Hard Mineral Resources Act and updates to NOAA's permitting process, which streamline the path toward commercial recovery, facilitating rapid growth in the critical minerals sector.
- ASPI's Market Positioning: ASP Isotopes CEO Paul Mann discussed the company's vertically integrated strategy to become a leading Western supplier of critical stable isotopes and nuclear fuels, highlighting the increasing importance of ASPI amid global supply concentration, particularly Russia's dominance in stable isotope production.
- Revenue Growth Potential: Mann pointed out that ASPI's nuclear medicine platform is generating double-digit year-over-year revenue growth, and the recent acquisition of Renergen provides access to one of the world's most concentrated helium resources, with 2026 poised to be a transformational year for the company as it advances toward scaled commercial production across multiple high-value critical material markets.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The class action against ASP Isotopes (NASDAQ: ASPI) continues after the Southern District of New York partially denied the defendants' motion to dismiss, indicating potential legal liabilities for the company and its executives, which could undermine investor confidence.
- False Statement Allegations: The lawsuit alleges that the company made materially false and misleading statements regarding its uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which may have long-term implications for its financial health.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, highlighting the potential impact of legal actions on corporate governance structures.
- Market Reaction: As the lawsuit progresses, investor confidence in the company's future may wane, leading to stock price volatility, reflecting the market's heightened scrutiny of the company's transparency and compliance.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The class action against ASP Isotopes Inc. (NASDAQ: ASPI) survives a partial dismissal motion in the Southern District of New York, indicating that securities fraud allegations against the company and its executives remain valid, potentially exposing the company to significant legal liabilities.
- False Statement Allegations: The lawsuit alleges that the company made materially false and misleading statements regarding its uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which could lead to severe losses for investors.
- Shareholder Rights Protection: Shareholders holding ASP Isotopes stock can seek corporate reforms and fund recovery at no cost, providing a legal remedy for affected investors that may influence the company's future governance structure.
- Market Reaction Potential: As the lawsuit progresses, market confidence in ASP Isotopes may be affected, leading to stock price volatility, prompting investors to closely monitor developments to assess potential financial impacts and investment risks.
See More
Investigation into ASP Isotopes Shareholder Rights
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of ASP Isotopes Inc. breached their fiduciary duties to shareholders, potentially impacting corporate governance and shareholder rights.
- Legal Fee Arrangement: The firm commits to handling matters on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal fees, thereby reducing the financial burden of participation.
- Importance of Participation: Shareholder involvement can drive improvements in company policies and oversight mechanisms, enhancing transparency and accountability, which ultimately boosts shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors.
See More
ASP Isotopes Stock Rises on Nuclear Energy Agreement
- Stock Surge: ASP Isotopes Inc. (NASDAQ:ASPI) shares rose 6.65% to $5.45 today after announcing a non-binding memorandum of understanding with a large U.S. energy company, indicating strong market optimism regarding future collaborations.
- Annual Performance: The stock has increased by 37.19% over the past year, although it remains closer to its 52-week low than its high, suggesting that investor interest in the company's nuclear energy potential could drive future price recovery.
- Technical Indicator Analysis: Currently, ASPI is trading 2.8% above its 20-day simple moving average but 22.2% below its 100-day average, reflecting a short-term bounce while indicating that the long-term trend still requires improvement, prompting cautious investor sentiment.
- Future Earnings Outlook: The upcoming earnings report on March 30, 2026, is expected to show an EPS loss of 14 cents with revenue estimated at $2.03 million, up from $1.19 million year-over-year, suggesting that while profitability remains a challenge, market confidence in future growth may strengthen.
See More
Quantum Leap Energy Signs Agreement with Utility for Nuclear Fuel Production
- Nuclear Fuel Production Expansion: Quantum Leap Energy has signed a memorandum of understanding with an unnamed utility to develop advanced nuclear fuel cycle facilities in the U.S., focusing on producing high-assay low-enriched uranium (HALEU) and low-enriched uranium plus (LEU+), which are essential for next-generation reactors, thereby enhancing domestic nuclear fuel production capabilities.
- Supporting Future Reactor Designs: The agreement aims to support next-generation reactor technologies and is expected to supply LEU+ fuel to existing nuclear facilities currently using conventional low-enriched uranium, reflecting a commitment to strengthening domestic nuclear fuel production and reducing reliance on overseas suppliers.
- Rising Market Demand: As developers work on advanced reactors and small modular designs, the demand for enriched uranium is increasing, with industry participants and policymakers emphasizing the importance of bolstering domestic production to meet future energy needs.
- Positive Market Reaction: ASPI's stock rose 0.7% in Friday's premarket trading, and retail sentiment on Stocktwits shifted from 'bearish' to 'neutral', indicating growing market confidence in the company's future prospects.
See More
RedChip Show to Feature Interviews with TMC and ASPI
- TMC's Strategic Role: TMC CFO Craig Shesky emphasized the company's importance in addressing U.S. critical mineral dependence during the RedChip show, particularly through the development of polymetallic nodule resources in the Clarion Clipperton Zone, which could provide a long-term domestic supply of nickel, copper, cobalt, and manganese, thereby enhancing the U.S.'s strategic position amid geopolitical competition.
- Regulatory Framework Progress: Shesky noted TMC's advancements under the U.S. Deep Seabed Hard Mineral Resources Act and updates to NOAA's permitting process, which streamline the path toward commercial recovery, facilitating rapid growth in the critical minerals sector.
- ASPI's Market Positioning: ASP Isotopes CEO Paul Mann discussed the company's vertically integrated strategy to become a leading Western supplier of critical stable isotopes and nuclear fuels, highlighting the increasing importance of ASPI amid global supply concentration, particularly Russia's dominance in stable isotope production.
- Revenue Growth Potential: Mann pointed out that ASPI's nuclear medicine platform is generating double-digit year-over-year revenue growth, and the recent acquisition of Renergen provides access to one of the world's most concentrated helium resources, with 2026 poised to be a transformational year for the company as it advances toward scaled commercial production across multiple high-value critical material markets.
See More
